Marie-Louise Kirkegaard Mikkelsen

Marie-Louise Kirkegaard Mikkelsen

Auto-generated profile, based on publicly available information

Marie-Louise Kirkegaard Mikkelsen

Biomathematics and Statistics Scotland, Aberdeen, United Kingdom

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MMMarie-Louise K Mikkelsen
Marie-Louise K Mikkelsen
GBGabriele Berg-Beckhoff
Gabriele Berg-Beckhoff
PFPeder Frederiksen
Peder Frederiksen
GHGraham Horgan
Graham Horgan
RORuairi O'Driscoll
Ruairi O'Driscoll
SLSofus C. Larsen
Sofus C. Larsen
Activity trackers such as the Fitbit Charge 2 enable users and researchers to monitor physical activity in daily life, which could be beneficial for changing behaviour. However, the accuracy of the Fitbit Charge 2 in a free-living environment is largely unknown. To investigate the agreement between Fitbit Charge 2 and ActiGraph GT3X for the estimation of steps, energy expenditure, time in sedentary behaviour, and light and moderate-to-vigorous physical activity under free-living conditions, and further examine to what extent placing the ActiGraph on the wrist as opposed to the hip would affect the findings. 41 adults (n = 10 males, n = 31 females) were asked to wear a Fitbit Charge 2 device and two ActiGraph GT3X devices (one on the hip and one on the wrist) for seven consecutive days and fill out a log of wear times. Agreement was assessed through Bland-Altman plots combined with multilevel analysis. The Fitbit measured 1,492 steps/day more than the hip-worn ActiGraph (limits of agreement [LoA] = -2,250; 5,234), while for sedentary time, it measured 25 min/day less (LoA = -137; 87). Both Bland-Altman plots showed fixed bias. For time in light physical activity, the Fitbit measured 59 min/day more (LoA = -52;169). For time in moderate-to-vigorous physical activity, the Fitbit measured 31 min/day less (LoA = -132; 71) and for activity energy expenditure it measured 408 kcal/day more than the hip-worn ActiGraph (LoA = -385; 1,200). For the two latter outputs, the plots indicated proportional bias. Similar or more pronounced discrepancies, mostly in opposite direction, appeared when comparing to the wrist-worn ActiGraph. Moderate to substantial differences between devices were found for most outputs, which could be due to differences in algorithms. Caution should be taken if replacing one device with another and when comparing results.

21 December 2017 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
SLSofus C. Larsen
Sofus C. Larsen
MMM-Lk Mikkelsen
M-Lk Mikkelsen
PFP Frederiksen
P Frederiksen
BHBerit Lilienthal Heitmann
Berit Lilienthal Heitmann

30 September 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
SSSarah Ellen Scott
Sarah Ellen Scott
CDCristiana Duarte
Cristiana Duarte
JEJorge Encantado
Jorge Encantado
EEElizabeth H Evans
Elizabeth H Evans
MHMarja Harjumaa
Marja Harjumaa
RSR James Stubbs
R James Stubbs
Introduction: Obesity and associated diseases place a severe burden on healthcare systems. Behavioural interventions for weight loss (WL) are successful in the short term but often result in weight regain over time. Self-regulation of eating and activity behaviours may significantly enhance weight loss maintenance (WLM) and may be effectively augmented by contextual behavioural approaches to emotion regulation. The NoHoW trial tests the efficacy of a theoretically informed, evidence-based digital toolkit using a mobile-enabled website, activity trackers and Wi-Fi scales for WLM aiming to target (1) self-regulation and motivation, and (2) emotion regulation in adults who achieved clinically significant (≥5%) WL in the previous 12 months (initial body mass index (BMI) ≥25 kg/m 2 ). Methods and analysis: The study is an 18-month, 3-centre, 2×2 factorial single-blind, randomised controlled trial, which recruited 1627 participants achieving ≥5% WL between March 2017 and March 2018. Participants are randomly allocated to one of four arms: (1) self-monitoring only (self-weighing and activity tracker), (2) self-regulation and motivation, (3) emotion regulation or (4) combined self-regulation, motivation and emotion regulation. Participants attend four clinical investigation days at 0, 6, 12 and 18 months and are instructed to use the digital toolkit for 18 weeks during the first 6 months and at their discretion for the remaining 12 months. The primary outcome is change in weight (kg) at 12 months from baseline. Secondary outcomes are body composition (eg, bioimpedance analysis), health biomarkers (glycated haemoglobin, lipids, blood pressure, hair cortisol), dietary intake, physical activity, sleep, motivational, self-regulatory, emotion regulatory moderators/mediators of WLM, engagement, user experience, acceptability and cost-effectiveness of the interventions. Ethics and dissemination: Ethical approval was granted by Institutional Ethics Committees at the Universities of Leeds (17–0082; 27 February 2017), Lisbon (17/2016; 20 February 2017) and Capital Region of Denmark (H-16030495, 8 March 2017). Results will be published in scientific journals. Trial registration number: ISRCTN88405328 .

6 September 2021 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Open access
PDF file
AUAnja Ussing
Anja Ussing
MMMarie-Louise Kirkegaard Mikkelsen
Marie-Louise Kirkegaard Mikkelsen
BVBrigitta Rasmussen Villumsen
Brigitta Rasmussen Villumsen
JWJohnny Wejlgaard
Johnny Wejlgaard
PBPernille Envold Bistrup
Pernille Envold Bistrup
TBThomas Bandholm
Thomas Bandholm
Background: Androgen deprivation therapy (ADT) in patients with prostate cancer can have several debilitating side effects. Supervised exercise is recommended to ameliorate these negative effects. Objective: To systematically evaluate the effect of supervised exercise therapy compared to no exercise therapy in patients with prostate cancer undergoing ADT, primarily according to the patient critical outcomes, ‘disease-specific quality of life’ and ‘walking performance’ measured at end of treatment. Methods: We searched PubMed/Medline, Embase, Cochrane Library, Cinahl and Pedro, to identify randomised controlled trials (RCTs), which investigated the effect of supervised exercise therapy compared to no exercise therapy in patients with prostate cancer receiving ADT, last search: June 2021. Two independent reviewers extracted data, and assessed risk of bias using Cochrane Risk of Bias Tool and evaluated the certainty of evidence using the GRADE-method. Results: Eigthteen RCTs (n = 1477) comprised patients with prostate cancer stages T1-T4 were included in the meta-analyses. Compared to no exercise therapy, supervised exercise therapy showed clinically relevant improvements in ‘disease-specific quality of life’ and ‘walking performance’. The standardised mean differences were 0.43 (95% confidence interval (CI): 0.29, 0.58) and −0.41 (95% CI: −0.60, −0.22), respectively. The overall certainty of evidence was moderate due to serious risk of bias. Conclusions: Evidence of moderate quality shows that supervised exercise therapy probably is superior to no exercise therapy in improving ‘disease-specific quality of life’ and ‘walking performance’ in patients with prostate cancer undergoing ADT. The results apply to all patients receiving androgen deprivation therapy regardless of cancer stage. The results support a strong recommendation for supervised exercise therapy for managing side effects in this population. Protocol registration: NKR-38-Focused-questions-PICOs-for-updating1.ashx (sst.dk)

CKChristoffer Bruun Korfitsen
Christoffer Bruun Korfitsen
MMMarie-Louise Kirkegaard Mikkelsen
Marie-Louise Kirkegaard Mikkelsen
AUAnja Ussing
Anja Ussing
KWKaren Christina Walker
Karen Christina Walker
JRJeanett Friis Rohde
Jeanett Friis Rohde
Mina HändelMina Händel
Mina Händel
The Danish Health Authority develops clinical practice guidelines to support clinical decision-making based on the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system and prioritizes using Cochrane reviews. The objective of this study was to explore the usefulness of Cochrane reviews as a source of evidence in the development of clinical recommendations. Evidence-based recommendations in guidelines published by the Danish Health Authority between 2014 and 2021 were reviewed. For each recommendation, it was noted if and how Cochrane reviews were utilized. In total, 374 evidence-based recommendations and 211 expert consensus recommendations were published between 2014 and 2021. Of the 374 evidence-based recommendations, 106 included evidence from Cochrane reviews. In 28 recommendations, all critical and important outcomes included evidence from Cochrane reviews. In 36 recommendations, a minimum of all critical outcomes included evidence from Cochrane reviews, but not all important outcomes. In 33 recommendations, some but not all critical outcomes included evidence from Cochrane reviews. Finally, in nine recommendations, some of the important outcomes included evidence from Cochrane reviews. In almost one-third of the evidence-based recommendations, Cochrane reviews were used to inform clinical recommendations. This evaluation should inform future evaluations of Cochrane review uptake in clinical practice guidelines concerning outcomes important for clinical decision-making.

14 January 2020 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
SLSofus C. Larsen
Sofus C. Larsen
GHGraham Horgan
Graham Horgan
MMMarie-Louise K. Mikkelsen
Marie-Louise K. Mikkelsen
APAntonio Palmeira
Antonio Palmeira
SSSarah Scott
Sarah Scott
BHBerit Lilienthal Heitmann
Berit Lilienthal Heitmann